secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001683168-24-003192
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences reports Q1 2024 net loss of $1.2M; cash at $7.8M
--------------------------------------------------------------------

- Net loss of approximately $1.2M for Q1 2024; R&D expenses up 58.6% to $0.9M on DNase preclinical work.
- Ended quarter with $7.8M cash; advancing DNase oncology program towards Phase 1 for solid tumors.
- Expects multiple preclinical data readouts in H2 2024 to guide clinical development strategy.
- G&A expenses decreased 9.8% to $0.8M compared to prior year quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316824003192/0001683168-24-003192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316824003192/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-003192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer